Clinical trials: Relapsed
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Opioid Use Disorder, Substance Use Disorders
Minds and Mentors Program- R33
The proposed research effort will: The purpose of this study is as follows: 1. Test the effectiveness of the Minds and Mentors Program in a group treatment trial in which individuals using medications for opioid use disorder…
- Conditions
- Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment
- Trial name
- MiMP (NCT05363371)
- Testing
- Minds and Mentors, Twelve Step Intervention Group
- Where
- 4 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Alabama, Tuscaloosa
Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to…
- Trial name
- NCT05042934
- Testing
- Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Lymphomas
Long-term Registry of Patients Treated With Loncastuximab Tesirine
Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.
- Trial name
- NCT05160064
- Where
- United States
- Sponsor
- ADC Therapeutics S.A.
CNS Lymphoma, Primary Central Nervous System Lymphoma
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma.
- Conditions
- CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- Trial name
- NCT05351593
- Testing
- Tafasitamab, Lenalidomide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- James Rubenstein
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT07516093
- Testing
- NX-5948, Pirtobrutinib
- Where
- 6 sites in United States
- Volunteers
- 620 people
- Sponsor
- Nurix Therapeutics, Inc.
Lymphoma, T-Cell, Peripheral
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2.
- Trial name
- NCT03742921
- Testing
- Istodax
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- ALPINE (NCT03734016)
- Testing
- Zanubrutinib, Ibrutinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 652 people
- Sponsor
- BeiGene
Acute Lymphoblastic Leukemia (ALL)
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of Phase 1b of this study is to: Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia…
- Trial name
- NCT02303821
- Testing
- Carfilzomib, Dexamethasone, Mitoxantrone
- Where
- 122 sites in United States, Argentina and 31 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Small Cell Lung Cancer
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes.
- Trial name
- NCT01417806
- Testing
- Topotecan and Pasireotide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- South Florida Veterans Affairs Foundation for Research and Education
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
B-Cell Acute Lymphoblastic Leukemia, Adult
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
- Trial name
- NCT06696833
- Testing
- QH10304-BAL-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Solid Tumor Cancers
A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours
The purpose of this clinical trial is to investigate the treatment for adult patients suffering from advanced or metastatic solid tumours and has 2 parts to the study: the Phase 1 where ascending doses of the experimental study…
- Trial name
- APM-CT001 (NCT07688148)
- Testing
- TAX2
- Where
- 4 sites in Belgium, France
- Volunteers
- 48 people
- Sponsor
- Apmonia Therapeutics
Mantle Cell Lymphoma
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits…
- Trial name
- NCT07377578
- Testing
- Rocbrutinib, Ibrutinib, Acalabrutinib
- Where
- 2 sites in China
- Volunteers
- 394 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis, Relapsing-Remitting
Worms for Immune Regulation of Multiple Sclerosis
The purpose of this study is to determine whether people with MS who are exposed to a small number of hookworms will have less inflammation and less MS disease activity.
- Trial name
- WIRMS (NCT01470521)
- Testing
- Hookworm larvae
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- University of Nottingham
Neuroblastoma
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
There is currently no curative treatment for children with relapsed/refractory neuroblastoma, and for these children the 5 year survival rate is <10%. As such, new therapeutic approaches are needed to treat these children.
- Trial name
- NCT00486564
- Testing
- Nifurtimox
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Acute Lymphoblastic Leukemia, B-cell Lymphoma
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04814004
- Testing
- hCD19.IL15.CAR-iNKT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Kai Lin Xu; Jun Nian Zheng
Relapsed/Refractory B-cell Malignancies
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed/Refractory B-cell Malignancies
- Trial name
- NCT07763938
- Testing
- CD19/CD20 Dual-Target in vivo CAR-T Lentiviral
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.